PRECISION NEUROLOGY

ESCAPE Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of precision small molecule therapies to treat genetically defined subpopulations in neurodegenerative diseases. We believe that developing therapies precisely targeted towards a perturbed pathway or genetic variant will ultimately address the root cause of disease, thereby potentially improving probability of success compared to less-selective approaches or those that target downstream manifestations of disease.

Executive Management

Julie Anne Smith
President & Chief Executive Officer
Anthony M. Rimac
Chief Financial Officer
Carrolee Barlow, MD, PhD
Chief Medical Officer
Paul Wren, PhD
Chief Scientific Officer

Senior Management

Brian Edquist
Vice President – R&D Operations
Holly Carlisle, PhD
Head of Biology
Jacob B. Schwarz, PhD
Head of Chemistry

Board of Directors

Laura Brass, PhD
Senior Investment Partner, Novartis Venture Fund
Perry Karsen
Gladstone Institutes
Peter Moldt, PhD
Partner, Novo Ventures
Julie Anne Smith
President & Chief Executive Officer
Peter Thompson, MD
Private Equity Partner,
OrbiMed
R. Sanders (Sandy) Williams, MD
Independent Director
Asish K. Xavier, PhD
Vice President, Venture Investments Johnson
& Johnson Innovation – JJDC, Inc.

Contact

4000 Shoreline Court, Suite 400 South San Francisco, CA 94080 650-431-0100 info@escapebio.com